

Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.

Title: Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.

Publication year: 2020

Journal: Journal of Crohn's & colitis

Authors: Hôpital Saint-Louis, Department of Gastroenterology, APHP, Université de Paris, France.

Society: European Respiratory Society

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1093/ecco-jcc/jjaa150

PMID: 32722757

Source: <https://pubmed.ncbi.nlm.nih.gov/32722757/>

J Crohns Colitis J Crohns Colitis 3817 pheoup 101318676 eccojc Journal of Crohn's & Colitis 1873-9946 1876-4479 pmc-is-collection-domain yes pmc-collection-title Oxford University Press - PMC COVID-19 Collection PMC7454473 PMC7454473.1 7454473 7454473 32722757 10.1093/ecco-jcc/jjaa150 jjaa150 1 Original Article AcademicSubjects/MED00260 Care of the Patient with IBD Requiring Hospitalization During the COVID-19 Pandemic Allez Matthieu 1 Fleshner Phillip 2 Geary Richard 3 <http://orcid.org/0000-0002-3948-6488> Lakatos Peter L 4 Rubin David T 5 IOIBD 1 Hôpital Saint-Louis, Department of Gastroenterology, APHP, Université de Paris, France 2 Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA 3 Department of Medicine, University of Otago, Christchurch, New Zealand 4 McGill University, Division of Gastroenterology Department of Medicine, Montreal, Canada and Semmelweis University, 1st Department of Medicine, Budapest, Hungary 5 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA Corresponding Author David T. Rubin, MD 5841 S. Maryland Avenue, MC 4076, Chicago, IL 60637 773-702-2950 drubin@medicine.bsd.uchicago.edu 29 7 2020 364151 jjaa150 02 6 2020 28 08 2020 31 08 2020 01 09 2020 © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. Abstract The management of IBD has been highly impacted in the context of the COVID-19 pandemic, with restriction of hospitalizations and unprecedented redeployment of healthcare resources. Hospital admissions of IBD patients should be limited to reduce the risks of coronavirus transmission. However, delaying hospitalization of IBD patients with severe or complicated disease may increase the risk of poor outcomes. Delaying surgery in some cases may increase the risk of disease progression, post-operative morbidity and disease complications. IBD patients who are infected with SARS-CoV-2 may have a higher risk of poor outcomes than the general population, potentially related to concomitant medications, especially corticosteroids. There is no evidence today that IBD patients with COVID-19 have worse outcomes if they receive immunosuppressant medications including thiopurines, biologics and novel small molecules. This article summarizes recommendations by the international membership of IOIBD regarding hospitalizations of IBD patients, either for active or complicated IBD or severe COVID-19, and for management of IBD patients according to SARS-CoV-2 infectious status.